Targeted drug therapy in nonsmall cell lung cancer: clinical significance and possible solutions-part II (role of nanocarriers)

Nonsmall cell lung cancer (NSCLC) accounts for 80-85% of the cases of lung cancer. The conventional therapeutic effective dosage forms used to treat NSCLC are associated with rigid administration schedules, adverse effects, and may be associated with acquired resistance to therapy. Nanocarriers may...

Full description

Bibliographic Details

Published in:	Expert opinion on drug delivery Vol. 18; no. 1; pp. 103 - 118
Main Authors:	Yadav, Khushwant S., Upadhya, Archana, Misra, Ambikanandan
Format:	Journal Article
Language:	English
Published:	England Taylor & Francis 02.01.2021
Subjects:	animal studies cell line studies clinical trials gene delivery Nanocarriers NSCLC gene delivery cell line studies animal studies clinical trials NSCLC Nanocarriers
ISSN:	1742-5247, 1744-7593, 1744-7593
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!